Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, persists as a challenging world health crisis. Prevention, diagnosis, and treatment hinge on the ability to effectively detect SARS-CoV-2 and related health implications effectively and efficiently. Therefore, Codetta and the NCCU Advanced Center for COVID-19 Related Disparities (ACCORD) will collaborate to make technologies for detection of COVID and assessment of COVID related health issues more accessible and efficient.
The Research Triangle Park, North Carolina based start-up is developing an integrated platform of reagents, hardware, and software designed to enable highly multiplexed, quantitative, simultaneous multi-omic analyses. In collaboration with NCCU, Codetta will use the funding from the North Carolina Collaboratory to enable detection of a panel of respiratory infectious diseases, as well as severity of host response and potential impact of long-COVID.
“We are privileged to be collaborating with Dr. Deepak Kumar and colleagues at NCCU ACCORD,” said TJ Johnson, CEO at Codetta. “This initiative directly aligns with Codetta’s purpose, to bring highly-complex medical and non-medical molecular testing to people and places everywhere.”
The North Carolina Collaboratory awarded NCCU and Codetta the grant through their Business-Academic Partnership Program, aimed to address the public health and economic impacts of COVID-19 in North Carolina.
“The ability to research and diagnose infections with clinically similar presentation to COVID-19 and rapidly identify those at high risk for more serious health implications, both short and long term, will provide a powerful tool to bring improved health care across North Carolina and beyond,” said Dr. Deepak Kumar, Principal Investigator at NCCU. “We’re looking forward to collaborating with Codetta to uncover new information about this disease and make testing more accessible to all.”
For more information, visit www.codettabio.com.